How are CYP2C19 and Langlebigkeit related?

CYP2C19 is a cytochrome P450 enzyme involved in the metabolism of many drugs (e.g., clopidogrel, proton pump inhibitors). Genetic variants (e.g., *2, *3) define metabolizer phenotypes (poor, intermediate, normal, ultrarapid). A direct link between CYP2C19 and longevity is not well established. Some studies suggest that certain variants may modulate risk for cardiovascular events or gastrointestinal diseases, which could indirectly affect lifespan. However, robust longitudinal evidence directly associating CYP2C19 with overall longevity is lacking. The provided context does not contain specific information on CYP2C19 and longevity. Therefore, the evidence level is unclear. Clinically, pharmacogenetic implications are more relevant: poor metabolizers may require dose adjustments. Claims about life extension based solely on CYP2C19 status are not supported by current data.